Table 2 Univariate analysis of enrolled patients

Postoperative capecitabine duration

4.65 ± 6.75

0.91 (0.86, 0.98), 0.014

0.90 (0.84, 0.97), 0.0043

  0

143 (55.64%)

1.0

1.0

   ≤ 12 weeks

79 (30.74%)

0.52 (0.36, 0.98), 0.030

0.48 (0.24, 0.99), 0.046

   ≤ 24 weeks

35 (13.62%)

0.26 (0.19, 0.70), 0.007

0.09 (0.01, 0.67), 0.018

Gender

  Male

161 (62.65%)

1.0

1.0

  Female

96 (37.35%)

1.07 (0.58–1.68), 0.21

1.12 (0.60, 2.08), 0.73

Age (years)

75.83 ± 4.60

1.04 (0.73–1.44), 0.77

1.06 (0.99, 1.12), 0.080

   ≥ 70, < 75

114 (44.36%)

1.0

1.0

   ≥ 75, < 80

84 (32.68%)

1.23 (0.73–2.88), 0.079

1.57 (0.77, 3.19), 0.21

   ≥ 80

59 (22.96%)

1.42 (0.75–3.13), 0.23

1.79 (0.83, 3.87), 0.14

T stage

  1–2

11 (4.28%)

1.0

1.0

  3

211 (82.10%)

1.40 (0.65–5.35), 0.42

1.30 (0.31, 5.44), 0.71

  4

35 (13.62%)

1.22 (0.92–5.57), 0.069

1.13 (0.23, 5.62), 0.88

N stage

  0

128 (49.81%)

1.0

1.0

  1

104 (40.47%)

1.10 (0.67–3.64), 0.45

1.77 (0.85, 3.67), 0.13

  2

25 (9.73%)

4.04 (1.93–8.99), < 0.0001

5.31 (2.42, 11.64), < 0.0001

Stage

  II

128 (49.81%)

1.0

1.0

  III

129 (50.19%)

2.19 (1.13, 4.66), 0.017

2.45 (1.26, 4.78), 0.0083

Histological type

  Common type

221 (85.99%)

1.0

1.0

  Special type

36 (14.01%)

1.28 (0.75–2.96), 0.061

1.69 (0.83, 3.44), 0.15

CEA

  Normal

163 (63.42%)

1.0

1.0

  Elevated

94 (36.58%)

1.29 (0.88–2.42), 0.38

1.15 (0.62, 2.12), 0.66

CA199

  Normal

209 (81.64%)

1.0

1.0

  Elevated

47 (18.36%)

2.68 (1.98–3.93), 0.0075

2.04 (1.04, 3.98), 0.037

Charlson comorbidity index

   ≤ 4

197 (76.65%)

1.0

1.0

   > 4

60 (23.35%)

1.18 (0.61–3.09), 0.87

1.05 (0.50, 2.19), 0.90

MMR status

  dMMR

20 (7.78%)

1.0

1.0

  pMMR

185 (71.98%)

0.79 (0.42, 1.93), 0.57

0.51 (0.21, 1.23), 0.1338

  Unknown

52 (20.23%)

0.67 (0.29, 1.84), 0.12

0.63 (0.22, 1.76), 0.3769